Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b Multicenter, Randomized, Placebo- Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis

Trial Profile

A Phase 2b Multicenter, Randomized, Placebo- Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Icotrokinra (Primary)
  • Indications Ulcerative colitis
  • Focus Therapeutic Use
  • Acronyms ANTHEM-UC
  • Sponsors Janssen Research & Development; Janssen-Cilag

Most Recent Events

  • 10 Mar 2025 Results published in the Johnson & Johnson media release.
  • 10 Mar 2025 Primary endpoint has been met. (Percentage of Participants with Clinical Response at Week 12), according to Johnson & Johnson media release.
  • 07 Nov 2024 According to a Protagonist Therapeutics media release, top line results for the Phase 2b ANTHEM is expected in Q1 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top